Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that remains incurable, despite decades of basic and clinical research. Key stakeholders—including the US National ...
After raising questions surrounding dosing levels, the FDA has freed Amylyx’s early-stage amyotrophic lateral sclerosis (ALS) ...
Zydus Lifesciences added 1.10% to Rs 987.60 after the company said that the USFDA had granted orphan drug designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for the treatment of amyotrophic ...
The Standard-Times on MSN1d
New Bedford man stole over $450K from disabled veteran. Here's what we know.Hundreds of thousands in monthly veteran benefits were stolen by New Bedford man. Here's what he was sentenced: ...
Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in 2025.
Hosted on MSN1d
FDA lifts clinical hold on Amylyx’s Phase I ALS trialThis is the latest venture for Amylyx into the ALS field after its previous therapy Relyvrio was pulled from the market in ...
GlobalData on MSN2d
FDA approves Zydus’ Phase IIb trial of Usnoflast for ALS treatmentThe US Food and Drug Administration (FDA) has granted approval for Zydus Lifesciences to proceed with a randomised Phase IIb ...
A New Bedford man was sentenced to prison for conspiring to steal and then depositing over $450,000 from a U.S. Marine ...
WWLP Springfield on MSN4d
New Bedford man sentenced to prison for stealing veteran’s disability benefitsA New Bedford man was sentenced to prison in federal court on Friday for stealing over $450,000 in disability benefits that ...
Ahmedabad: Zydus, a discovery-based, global pharmaceutical company has announced that it has received approval from USFDA to ...
Denali Therapeutics Inc.'s stock remains stable despite trial setback in ALS. BLA filing for MPS II treatment on track. Click ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback